Therapeutic Potential of GLP-1 Receptor Agonists for Substance Use Disorders

Presenter: Christian Henderson, PhD, Keck School of Medicine, University of Southern California (read more about Dr. Henderson here)

This presentation will summarize emerging evidence for the efficacy of GLP-1 receptor agonists for substance use disorders. Recent and ongoing Phase 2 clinical trials will be reviewed, and key clinical and implementation issues discussed.

Learning objectives

Identify at least three (3) potential therapeutic benefits of GLP-1-based therapies for individuals with substance use disorder.

Describe at least three (3) common side effects and three (3) safety considerations for GLP-1-based therapies.

Explain at least three (3) GLP-1-based therapies currently under evaluation for substance use disorder.

1.5 CE/CME available!

Sponsored by the Northwest and Pacific Southwest ATTCs and the Western States Node of the NIDA Clinical Trials Network